Previous 10 | Next 10 |
Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the de...
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and live webcast ...
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxof...
Investing in a startup does not make you an entrepreneur any more than buying a grand piano makes you a concert pianist .” ― Jeffrey Fry Today we revisit Stemline Therapeutics ( STML ), a member of the 20-stock Busted IPO Forum model portfolio. The stock jumped over 15...
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, was select...
Stemline Therapeutics, Inc. (NASDAQ: STML ): Q4 GAAP EPS of -$0.92 misses by $0.18. More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has exclusively licensed worldwide rights to develop...
NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...
Noteworthy events during the week of February 17 - 23 for healthcare investors. More news on: Allakos, Stemline Therapeutics, Aimmune Therapeutics, Healthcare stocks news, , Read more ...
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the European Medicines Agency (EMA) has completed its va...
News, Short Squeeze, Breakout and More Instantly...
Stemline Therapeutics Inc. Company Name:
STML Stock Symbol:
NASDAQ Market:
Stemline Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) r...
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. That has intrepid investors wondering if their recent gains could be the beginning of something much larger. Data source: Yahoo! Finance. It isn't unusual to see small-cap...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...